Docoh
Loading...
Sign up Log in

PCSA Processa Pharmaceuticals

Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The Company acquired the assets of Promet Therapeutics, LLC in October of 2017 and assembled a proven regulatory science development team, management team, and Board of Directors. The Processa drug development team members have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. PCS-499 represents the first Processa drug that can potentially be used in several unmet medical need conditions.

Company profile

Ticker
PCSA
Exchange
NASDAQ
Website
processapharmaceuticals.com
CEO
David Young
Employees
Incorporated
Delaware
Location
Maryland
Fiscal year end
Dec 31
Sector
Manufacturing > Heavy Duty Truck Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Viatris • Bristol-Myers Squibb • Warner Chilcott ...
Former names
Heatwurx, Inc.
SEC CIK
0001533743
Corporate docs

PCSA stock data

(
)

News

Pro users get this 30m faster
45 Biggest Movers From Yesterday
25 Jun 21
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares surged 105.3% to close at $3.51 on Thursday after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.
Processa Pharmaceuticals In-Licenses Ocuphire's Anticancer Agent
17 Jun 21
Processa Pharmaceuticals Says Enters Into Licensing Agreement With Ocuphire Pharma For Development Of RX-3117
17 Jun 21
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ:OCUP) to license in RX-3117. RX-3117 is an oral, anticancer agent with an
12 Health Care Stocks Moving In Thursday's After-Market Session
10 Jun 21
Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
20 May 21

Press releases

Pro users get this 30m faster
Processa Pharmaceuticals to Present at "Zooming with LD Micro" Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET
27 Jul 21
HANOVER, MD, July 27, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced today that it will be presenting at the upcoming "Zooming with LD Micro" virtual investor event on Thursday, July
Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
6 Jul 21
HANOVER, MD, July 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation will be given by
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
17 Jun 21
HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ:OCUP) to license in RX-3117.
Processa Set to Join Russell Microcap® Index
8 Jun 21
Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET
7 Jun 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

13 May 21
27 Jul 21
31 Dec 21

Financial summary

Financial statements Chart PCSA financial data
Quarter (USD)
 Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 23.05M 23.05M 23.05M 23.05M 23.05M 23.05M
Cash burn (monthly) (positive/no burn) (positive/no burn) 731.1K 1.38M 747.84K 403.36K
Cash used (since last report) n/a n/a 2.85M 5.39M 2.91M 1.57M
Cash remaining n/a n/a 20.2M 17.66M 20.14M 21.48M
Runway (months of cash) n/a n/a 27.6 12.8 26.9 53.2

Beta Read what these cash burn values mean

Recent insider trades

PCSA insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 Jul 21 James H Stanker RSU Common Stock Grant Aquire A No No 0 1,907 0 10,034
8 Jul 21 James H Stanker RSU Common Stock Grant Aquire A No No 0 12,858 0 12,858
8 Jul 21 James H Stanker RSU Common Stock Grant Aquire A No No 0 8,572 0 8,572
8 Jul 21 David Young RSU Common Stock Grant Aquire A No No 0 1,907 0 10,034
8 Jul 21 David Young RSU Common Stock Grant Aquire A No No 0 12,858 0 12,858
8 Jul 21 David Young RSU Common Stock Grant Aquire A No No 0 8,572 0 8,572
8 Jul 21 Wendy Guy RSU Common Stock Grant Aquire A No No 0 1,907 0 10,034
8 Jul 21 Wendy Guy RSU Common Stock Grant Aquire A No No 0 12,858 0 12,858
8 Jul 21 Wendy Guy RSU Common Stock Grant Aquire A No No 0 8,572 0 8,572
8 Jul 21 Patrick Lin RSU Common Stock Grant Aquire A No No 0 1,907 0 10,034
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

PCSA institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

92.9% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 20 3 +566.7%
Opened positions 17 3 +466.7%
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
 Current Prev Q Change
Total value 75.78M 52.6M +44.1%
Total shares 14.47M 13.32M +8.6%
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners
 Shares Value Change
David Young 11.44M $45.2M 0.0%
Manchester Management 1.13M $4.44M 0.0%
Yuhan (usa) 750K $2.96M 0.0%
AIGH Capital Management 387.1K $4.01M NEW
Solas Capital Management 200K $2.18M NEW
Vanguard 157.64K $1.72M NEW
Millennium Management 94K $1.03M NEW
Worth Venture Partners 90.97K $942K NEW
Essex Investment Management 72.91K $795K NEW
Janney Montgomery Scott 63.33K $690K NEW
Largest transactions
 Shares Bought/sold Change
AIGH Capital Management 387.1K +387.1K NEW
Solas Capital Management 200K +200K NEW
Vanguard 157.64K +157.64K NEW
Millennium Management 94K +94K NEW
Worth Venture Partners 90.97K +90.97K NEW
Essex Investment Management 72.91K +72.91K NEW
Janney Montgomery Scott 63.33K +63.33K NEW
Geode Capital Management 27.83K +27.83K NEW
Coastal Bridge Advisors 20K +20K NEW
Citadel Advisors 13.12K +13.12K NEW
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: agent, body, brand, broad, brought, budgeted, capecitabane, catabolism, central, chart, counsel, depreciation, devoting, earlier, efficient, efficiently, electronic, email, globe, government, guidance, inclusion, inflection, institutional, intake, invoice, leverage, litigation, local, magnitude, modified, notably, path, pipeline, policy, raw, Refractory, stability, Tract, uncertain, unplanned, unvested, unwanted, upper, warrant, wire
Removed: acceleration, acceptable, accrued, accurately, achievement, advantage, advisory, Akashi, amended, amendment, assumed, authority, automatically, bear, begun, borrowed, breach, bridge, calendar, collateral, collected, commitment, committed, comprising, conducting, consist, convert, converted, country, CRO, cure, cured, declaring, decreased, default, defined, delay, departure, dependent, diligence, disease, disrupt, disrupted, distribute, DKBK, DMD, drawn, Duchenne, Dystrophy, economy, event, existing, expenditure, factor, fiber, forfeited, forward, funded, hold, holder, investing, kind, limiting, line, listing, LOC, main, making, Managing, mandatorily, mature, Member, move, muscle, Muscular, Nasdaq, newly, notice, October, ongoing, opportunity, Organization, owing, payment, pediatric, permit, Pledge, pledged, PoC, preemptive, pro, promising, rata, receivable, receiving, regeneration, reimbursed, relating, released, relinquish, requesting, restricting, returned, reverse, revolving, satisfaction, scope, secured, seek, shortened, spend, spending, split, straight, strength, subscription, suspend, terminate, unable, uncertainty, unpaid, unregistered, valuable, volatility, working, World, worldwide
From filing 10-Q 2021 Q1

Financial reports

View all
10-Q
2021 Q1
Quarterly report
13 May 21
10-K/A
2020 FY
Annual report (amended)
7 Apr 21
10-K
2020 FY
Annual report
24 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
15 May 20
10-K
2019 FY
Annual report
5 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
14 May 19

Current reports

View all
8-K
Regulation FD Disclosure
15 Jul 21
8-K
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
17 Jun 21
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 21
8-K
Regulation FD Disclosure
9 Jun 21
8-K
Termination of a Material Definitive Agreement
26 May 21
8-K
Regulation FD Disclosure
20 May 21
8-K
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
13 May 21
8-K
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
24 Mar 21
8-K
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
18 Feb 21
8-K
Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
11 Jan 21

Registration and prospectus

View all
S-3
Shelf registration
30 Jun 21
S-8
Registration of securities for employees
30 Jun 21
424B3
Prospectus supplement
12 Apr 21
S-3
Shelf registration
1 Apr 21
D
$10.24M in equity / options, sold $10.24M, 18 investors
19 Feb 21
424B4
Prospectus supplement with pricing info
5 Oct 20
S-1/A
IPO registration (amended)
30 Sep 20
RW
Registration withdrawal request
25 Sep 20
8-A12B
Registration of securities on exchange
16 Sep 20
S-1/A
IPO registration (amended)
16 Sep 20

Proxies

DEFA14A
Additional proxy soliciting materials
26 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
DEF 14C
Information statement
27 May 20
PRE 14C
Preliminary information
15 May 20
DEF 14C
Information statement
25 Nov 19
PRE 14C
Preliminary information
12 Nov 19
DEF 14C
Information statement
18 Jul 19
PRE 14C
Preliminary information
2 Jul 19
DEF 14A
Definitive proxy
26 Apr 19

Other

View all
EFFECT
Notice of effectiveness
12 Jul 21
EFFECT
Notice of effectiveness
13 Apr 21
CORRESP
Correspondence with SEC
6 Apr 21
UPLOAD
Letter from SEC
4 Apr 21
EFFECT
Notice of effectiveness
2 Oct 20
CORRESP
Correspondence with SEC
28 Sep 20
CORRESP
Correspondence with SEC
28 Sep 20
CORRESP
Correspondence with SEC
24 Sep 20
CORRESP
Correspondence with SEC
21 Sep 20
CORRESP
Correspondence with SEC
21 Sep 20

Ownership

View all
4
Processa Pharmaceuticals / Robert Michael Floyd ownership change
9 Jul 21
4
Processa Pharmaceuticals / Sian Bigora ownership change
9 Jul 21
4
Processa Pharmaceuticals / Patrick Lin ownership change
9 Jul 21
4
Processa Pharmaceuticals / Wendy Guy ownership change
9 Jul 21
4
Processa Pharmaceuticals / David Young ownership change
9 Jul 21
4
Processa Pharmaceuticals / James H Stanker ownership change
9 Jul 21
4
Processa Pharmaceuticals / David Young ownership change
23 Jun 21
4
Processa Pharmaceuticals / Robert Michael Floyd ownership change
22 Jun 21
4
Processa Pharmaceuticals / Patrick Lin ownership change
22 Jun 21
4
Processa Pharmaceuticals / James H Stanker ownership change
22 Jun 21

Transcripts

2021 Q1
Earnings call transcript
14 May 21

Reddit threads

View all